論文原著

英　文

Ishihara O, Klein BM, Arce JC; Japanese Follitropin Delta Phase 2 Trial Group.
Randomized, assessor-blind, antimüllerian hormone-stratified, dose-response trial in Japanese in vitro fertilization/ intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta.
Fertil Steril. 115(6): 1478-1486, 2021

Ishihara O, Nelson SM, Arce JC.
Comparison of ovarian response to follitropin delta in Japanese and White IVF/ICSI patients.
Reprod Biomed Online. 2021 Sep 23:S1472-6483(21)00473-9. doi: 10.1016/j.rbmo.2021.09.014. Online ahead of print.

Ishihara O, Arce JC; Japanese Follitropin Delta Phase 3 Trial (STORK) Group.
Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial.
Reprod Biomed Online. 42(5): 909-918, 2021

Banker M, Dyer S, Chambers GM, Ishihara O, Kupka M, de Mouzon J, Zegers-Hochschild F, Adamson GD.
International Committee for Monitoring Assisted Reproductive Technologies (ICMART): world report on assisted reproductive technologies, 2013
Fertil Steril. 116(3): 741-756, 2021

Maeda E, Ishihara O, Tomio J, Miura H, Kobayashi Y, Terada Y, Murata K, Nomura K.
Cesarean delivery rates for overall and multiple pregnancies in Japan: A descriptive study using nationwide health insurance claims data.
J Obstet Gynaecol Res. 47(6): 2099-2109, 2021

Chambers GM, Dyer S, Zegers-Hochschild F, de Mouzon J, Ishihara O, Banker M, Mansour R, Kupka MS, Adamson GD.
International Committee for Monitoring Assisted Reproductive Technologies world report: assisted reproductive technology, 2014†.
Hum Reprod. 36(11): 2921-2934, 2021

Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillerm E, Golmard L, Goardon N, Sevenet N, Cabaret O, Harter P, Gonzalez-Martin A, Fujiwara K, Cecere SC, Colombo N, Marth C, Vergote I, Maenpaa J, Pujade-Lauraine E, Ray-Coquard I.
Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.
J Natl Cancer Inst. 113(7): 917-923, 2021

Virani S, Baiocchi G, Bowtell D, Cabasag CJ, Cho KR, Fortner RT, Fujiwara K, Kim JW, Köbel M, Kurtz JE, Levine DA, Menon U, Norquist BM, Pharoah PDP, Sood AK, Tworoger ST, Wentzensen N, Chanock SJ, Brennan P, Trabert B.
Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research.
Carcinogenesis. 42(6): 785-793, 2021

Akada K, Koyama N, Miura T, Fukunaga E, Miura Y, Aoshima K, Fujiwara K.
Real-world database analysis of the characteristics and treatment patterns of patients with endometrial cancer in Japan.
Curr Med Res Opin. 37(7): 1171-1178, 2021

duPont NC, Enserro D, Brady MF, Moxley K, Walker JL, Cosgrove C, Bixel K, Tewari KS, Thaker P, Wahner Hendrickson AE, Rubin S, Fujiwara K, Casey AC, Soper J, Burger RA, Monk BJ.
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
Gynecol Oncol. 2021 Nov 29;S0090-8258(21)01607-3. doi: 10.1016/j.ygyno.2021.11.013. Online ahead of print.

Fujiwara K, Fujiwara H, Yoshida H, Satoh T, Yonemori K, Nagao S, Matsumoto T, Kobayashi H, Bourgeois H, Harter P, Mosconi AM, Vazquez IP, Reinthaller A, Fujita T, Rowe P, Pujade-Lauraine E, Ray-Coquard I.
Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial.
J Gynecol Oncol. 2021 Sep;32(5):e82. doi: 10.3802/jgo.2021.32.e82.

Sakurai M, Satoh T, Nakamura Y, Takei Y, Takahashi S, Fujiwara H, Nakamura K, Kanuma T, Fujiwara K, Suzuki M.
Treatment-related leukemia after taxane and platinum therapy in gynecological cancer patients (Gynecologic Oncology Trial and Investigation Consortium 011).
J Obstet Gynaecol Res. 47(7): 2500-2508, 2021

Harter P, Mouret-Reynier MA, Pignata S, Cropet C, González-Martín A, Bogner G, Fujiwara K, Vergote I, Colombo N, Nøttrup TJ, Floquet A, El-Balat A, Scambia G, Guerra Alia EM, Fabbro M, Schmalfeldt B, Hardy-Bessard AC, Runnebaum I, Pujade-Lauraine E, Ray-Coquard I.
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Gynecol Oncol. 2021 Dec 21:S0090-8258(21)01673-5. doi: 10.1016/j.ygyno.2021.12.016. Online ahead of print.

Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, Leary A, Tinker AV, Jung KH, Madry R, Park SY, Anderson CK, Zohren F, Stewart RA, Wei C, Dychter SS, Monk BJ.
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Lancet Oncol. 22(7): 1034-1046, 2021

Monk BJ, Colombo N, Oza AM, Fujiwara K, Birrer MJ, Randall L, Poddubskaya EV, Scambia G, Shparyk YV, Lim MC, Bhoola SM, Sohn J, Yonemori K, Stewart RA, Zhang X, Perkins Smith J, Linn C, Ledermann JA.
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Lancet Oncol. 22(9): 1275-1289, 2021

Suzumori N, Sekizawa A, Takeda E, Samura O, Sasaki A, Akaishi R, Wada S, Hamanoue H, Hirahara F, Sawai H, Nakamura H, Yamada T, Miura K, Masuzaki H, Nakayama S, Kamei Y, Namba A, Murotsuki J, Yamaguchi M, Tairaku S, Maeda K, Kaji T, Okamoto Y, Endo M, Ogawa M, Kasai Y, Ichizuka K, Yamada N, Ida A, Miharu N, Kawaguchi S, Hasuo Y, Okazaki T, Ichikawa M, Izumi S, Kuno N, Yotsumoto J, Nishiyama M, Shirato N, Hirose T, Sago H.
Retrospective details of false-positive and false-negative results in non-invasive prenatal testing for fetal trisomies 21, 18 and 13
Eur J Obstet Gynecol Reprod Biol. 256: 75-81, 2021

Sasaki Y, Yamada T, Tanaka S, Sekizawa A, Hirose T, Suzumori N, Kaji T, Kawaguchi S, Hasuo Y, Nishizawa H, Matsubara K, Hamanoue H, Fukushima A, Endo M, Yamaguchi M, Kamei Y, Sawai H, Miura K, Ogawa M, Tairaku S, Nakamura H, Sanui A, Mizuuchi M, Okamoto Y, Kitagawa M, Kawano Y, Masuyama H, Murotsuki J, Osada H, Kurashina R, Samura O, Ichikawa M, Sasaki R, Maeda K, Kasai Y, Yamazaki T, Neki R, Hamajima N, Katagiri Y, Izumi S, Nakayama S, Miharu N, Yokohama Y, Hirose M, Kawakami K, Ichizuka K, Sase M, Sugimoto K, Nagamatsu T, Shiga T, Tashima L, Taketani T, Matsumoto M, Hamada H, Watanabe T, Okazaki T, Iwamoto S, Katsura D, Ikenoue N, Kakinuma T, Hamada H, Egawa M, Kasamatsu A, Ida A, Kuno N, Kuji N, Ito M, Morisaki H, Tanigaki S, Hayakawa H, Miki A, Sasaki S, Saito M, Yamada N, Sasagawa T, Tanaka T, Hirahara F, Kosugi S, Sago H; Japan N. I. P. T. Consortium.
Evaluation of the clinical performance of noninvasive prenatal testing at a Japanese laboratory.
J Obstet Gynaecol Res. 47(10): 3437-3446, 2021

Koshiba M, Watarai-Senoo A, Karino G, Ozawa S, Kamei Y, Honda Y, Tanaka I, Kodama T, Usui S, Tokuno H.
A Susceptible Period of Photic Day-Night Rhythm Loss in Common Marmoset Social Behavior Development.
Front Behav Neurosci. 2021 Feb 2;14:539411. doi: 10.3389/fnbeh.2020.539411. eCollection 2020.

Hosono S, Isayama T, Sugiura T, Kusakawa I, Kamei Y, Ibara S, Tamura M; Neonatal Resuscitation Committee, Japan Society of Perinatal, Neonatal Medicine.
Management of infants born to mothers with suspected or confirmed SARS-CoV-2 infection in the delivery room: A tentative proposal 2020.
Pediatr Int. 63(3): 260-263, 2021
Kusama K, Fukushima Y, Yoshida K, Azumi M, Yoshie M, Mizuno Y, Kajihara T, Tamura K.
PGE2 and Thrombin Induce Myofibroblast Transdifferentiation via Activin A and CTGF in Endometrial Stromal Cells.
Endocrinology. 2021 Dec 1;162(12):bqab207. doi: 10.1210/endocr/bqab207.

Gotoh O, Kiyotani K, Chiba T, Sugiyama Y, Takazawa Y, Nemoto K, Kato K, Tanaka N, Nomura H, Hasegawa K, Fujiwara K, Takamatsu S, Matsumura N, Noda T, Mori S.
Immunogenomic landscape of gynecologic carcinosarcoma.
Gynecol Oncol. 160(2): 547-556, 2021

Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, Matsumoto K, Ito K, Mandai M, Nakai H, Sakuragi N, Watari H, Takahashi N, Kato H, Hasegawa K, Yonemori K, Mizuno M, Takehara K, Niikura H, Sawasaki T, Nakao S, Saito T, Enomoto T, Nagase S, Suzuki N, Matsumoto T, Kondo E, Sonoda K, Aihara S, Aoki Y, Okamoto A, Takano H, Kobayashi H, Kato H, Terai Y, Takazawa A, Takahashi Y, Namba Y, Aoki D, Fujiwara K, Sugiyama T, Konishi I.
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
J Clin Oncol. 39(33): 3671-3681, 2021

Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yañez E, Gümüş M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Toker S, Li K, Keefe SM, Monk BJ; KEYNOTE-826 Investigators.
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
N Engl J Med. 385(20): 1856-1867, 2021

Suzuki M, Yagishita S, Sugihara K, Ogitani Y, Nishikawa T, Ohuchi M, Teishikata T, Jikoh T, Yatabe Y, Yonemori K, Tamura K, Hasegawa K, Hamada A.
Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis.
Clin Cancer Res. 27(14): 3970-3979, 2021

Yoshida H, Nishikawa T, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Hasegawa K, Yonemori K.
Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy.
Virchows Arch. 478(6): 1161-1171,2021

Takehara K, Matsumoto T, Hamanishi J, Hasegawa K, Matsuura M, Miura K, Nagao S, Nakai H, Tanaka N, Tokunaga H, Ushijima K, Watari H, Yokoyama Y, Kase Y, Sumino S, Suri A, Itamochi H, Takeshima N.
Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer.
J Gynecol Oncol. 2021 Mar;32(2):e21. doi: 10.3802/jgo.2021.32.e21. Epub 2021 Jan 6.

Okamoto A, Kondo E, Nakamura T, Yanagida S, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Tabata T, Takehara K, Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Suri A, Aoki D, Sugiyama T.
Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer.
J Gynecol Oncol. 2021 Mar;32(2):e16. doi: 10.3802/jgo.2021.32.e16. Epub 2020 Dec 10.

Yang C, Ikeda K, Horie-Inoue K, Sato W, Hasegawa K, Takeda S, Itakura A, Inoue S
Transcriptomic analysis of hormone-sensitive patient-derived endometrial cancer spheroid culture defines Efp as a proliferation modulator.
Biochem Biophys Res Commun. 548: 204-210, 2021

Takeiwa T, Mitobe Y, Ikeda K, Hasegawa K, Horie K, Inoue S.
Long Intergenic Noncoding RNA OIN1 Promotes Ovarian Cancer Growth by Modulating Apoptosis-Related Gene Expression.
Int J Mol Sci. 2021 Oct 18;22(20):11242. doi: 10.3390/ijms222011242.

Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, Matsumoto K, Ito K, Mandai M, Nakai H, Sakuragi N, Watari H, Takahashi N, Kato H, Hasegawa K, Yonemori K, Mizuno M, Takehara K, Niikura H, Sawasaki T, Nakao S, Saito T, Enomoto T, Nagase S, Suzuki N, Matsumoto T, Kondo E, Sonoda K, Aihara S, Aoki Y, Okamoto A, Takano H, Kobayashi H, Kato H, Terai Y, Takazawa A, Takahashi Y, Namba Y, Aoki D, Fujiwara K, Sugiyama T, Konishi I.
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
J Clin Oncol. 39(33): 3671-3681, 2021

Matsuura K, Inoue K, Hoshino E, Yasuda M, Hasegawa K, Okada Y, Baba Y, Kozawa E.
Utility of magnetic resonance imaging for differentiating malignant mesenchymal tumors of the uterus from T2-weighted hyperintense leiomyomas.
Jpn J Radiol. 2021 Nov 9. doi: 10.1007/s11604-021-01217-2. Online ahead of print.

Tsukahara Y, Namba A, Kamada H, Torii S, Tabata S, Yamasawa F, Sato K.
Factors that affect menarche in Japanese national-level track-and-field athletes.
Am J Hum Biol. 2021;e23622. https://doi.org/10.1002/ajhb.23622

Yasuda S, Inoue K, Iida S, Oikawa Y, Namba A, Isshiki M, Inoue I, Kamei Y, Shimada A, Noda M.
Differences in the birthweight of infants born to patients with early- or mid-to-late-detected gestational diabetes mellitus who underwent guideline-based glycemic control.
J Diabetes Complications. 2021 Apr;35(4):107850. doi: 10.1016/j.jdiacomp.2021.107850. Epub 2021 Jan 9.

Akiyama N, Shimura M, Yamazaki T, Harashima H, Fushimi T, Tsuruoka T, Ebihara T, Ichimoto K, Matsunaga A, Saito-Tsuruoka M, Yatsuka Y, Kishita Y, Kohda M, Namba A, Kamei Y, Okazaki Y, Kosugi S, Ohtake A, Murayama K.
Prenatal diagnosis of severe mitochondrial diseases caused by nuclear gene defects: a study in Japan.
Sci Rep. 11(1): 3531, 2021

Yoshida H, Shintani D, Fujiwara K.
Obesity is a predictive biomarker of poor benefit from single-agent bevacizumab therapy in recurrent ovarian cancer patients.
J BUON. 26(5): 1762-1767, 2021

Satake E, Koga K, Takamura M, Izumi G, Elsherbini M, Taguchi A, Makabe T, Takeuchi A, Harada M, Hirata T, Hirota Y, Wada-Hiraike O, Osuga Y.
The roles of polymorphonuclear myeloid-derived suppressor cells in endometriosis.
J Reprod Immunol. 2021 Nov;148:103371. doi: 10.1016/j.jri.2021.103371. Epub 2021 Sep 4.

Tamaru S, Jwa SC, Ono Y, Seki H, Matsui H, Fujii T, Iriyama T, Doi K, Sameshima H, Naruse K, Kobayashi H, Yoshida R, Nishi H, Hirata Y, Fukushima K, Hirakawa T, Nakano Y, Asakawa Y, Tsunoda Y, Oda T, Nii S, Fujii T, Kinoshita K, Kamei Y.
Feasibility of a mobile cardiotocogram device for fetal heart rate self-monitoring in low-risk singleton pregnant women.
J Obstet Gynaecol Res. 2021 Dec 5. doi: 10.1111/jog.15118. Online ahead of print.

Jwa SC, Takamura M, Kuwahara A, Kajihara T, Ishihara O.
Effect of endometrial preparation protocols on the risk of ectopic pregnancy for frozen embryo transfer.
Sci Rep. 2021 Aug 31;11(1):17453. doi: 10.1038/s41598-021-97044-6.

Jwa SC, Ishihara O, Kuwahara A, Saito K, Saito H, Terada Y, Kobayashi Y, Maeda E.
Cumulative live birth rate according to the number of receiving governmental subsidies for assisted reproductive technology in Saitama Prefecture, Japan: A retrospective study using individual data for governmental subsidies.
Reprod Med Biol. 20(4): 451-459, 2021

Jwa SC, Ishihara O, Kuwahara A, Saito K, Saito H, Terada Y, Kobayashi Y, Maeda E
Social capital and use of assisted reproductive technology in young couples: Ecological study using application information for government subsidies in Japan.
SSM-Population Health 16(2021) 100995. doi.org/10.1016/J.ssmph.2021.100995

Iba A, Maeda E, Jwa SC, Yanagisawa-Sugita A, Saito K, Kuwahara A, Saito H, Terada Y, Ishihara O, Kobayashi Y.
Household income and medical help-seeking for fertility problems among a representative population in Japan.
Reprod Health. 2021 Aug 3;18(1):165. doi: 10.1186/s12978-021-01212-w.

Ogawa K, Jwa SC, Morisaki N, Sago H.
Risk factors and clinical outcomes for placenta accreta spectrum with or without placenta previa.
Arch Gynecol Obstet. 2021 Aug 26. doi: 10.1007/s00404-021-06189-2. Online ahead of print.

Doi R, Kobayashi M, Ogawa K, Morisaki N, Jwa SC, Fujiwara T.
Validity of dietary patterns extracted from the food intake frequency questionnaires of Japanese pregnant women.
J Hum Nutr Food Sci. 2021; 9 (1): 1140

Motohashi T, Yabuno A, Michimae H, Ohishi T, Nonaka M, Takano M, Nishio S, Fujiwara H, Fujiwara K, Kondo E, Sugiyama T, Tabata T.
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial.
J Gynecol Oncol. 2021 Jan;32(1):e9. doi: 10.3802/jgo.2021.32.e9. Epub 2020 Nov 10.

Heong V, Tan TZ, Miwa M, Ye J, Lim D, Herrington CS, Iida Y, Yano M, Yasuda M, Ngoi NY, Wong SJ, Okamoto A, Gourley C, Hasegawa K, Tan DS, Huang RY.
A multi-ethnic analysis of immune-related gene expression signatures in patients with ovarian clear cell carcinoma.
J Pathol. 255(3): 285-295, 2021

Yano M, Miyazawa M, Ogane N, Ogasawara A, Hasegawa K, Narahara H, Yasuda M.
Up-regulation of HDAC6 Results in Poor Prognosis and Chemoresistance in Patients With Advanced Ovarian High-grade Serous Carcinoma.
Anticancer Res. 41(3): 1647-1654, 2021

Sato M, Shintani D, Hanaoka M, Sato S, Miwa M, Ogasawara A, Yabuno A, Kurosaki A, Yoshida H, Fujiwara K, Hasegawa K.
A pilot study of mobile digital colposcopy in Japanese patients with cervical intraepithelial neoplasm.
Mol Clin Oncol. 2021 Oct;15(4):207. doi: 10.3892/mco.2021.2370. Epub 2021 Aug 9.

Yoshida T, Takada K, Komine-Aizawa S, Kamei Y, Ishihara O, Hayakawa S.
Lactobacillus crispatus promotes invasion of the HTR-8/SVneo trophoblast cell line.
Placenta. 111: 76-81, 2021

邦　文

前田恵理、石原　理、左　勝則、李　延秀、小林廉毅
韓国における人工授精および生殖補助医療の公費負担状況　保険適用の背景と影響に関する訪問調査.
公衆衛生. 86(1): 84-90, 2021.

松田尚子、高村将司、左　勝則、瀬戸さち恵、吉田智昭、山口　哲、梶原　健、岡垣竜吾、亀井良政、石原　理
全腹腔鏡下子宮全摘術新規導入後の手術成績と経腟的検体摘出時間に与える因子の解析
埼玉産科婦人科学会雑誌51(2): 134-139, 2021

論文総説

邦　文

石原　理
産婦人科医から見た非侵襲的出生前検査（NIPT）の本質
上智大学生命倫理研究所　生命と倫理8: 37-45, 2021

石原　理
【医療スタッフが知っておきたい性的マイノリティと医療】性別違和、トランスジェンダーにおけるホルモン療法
医学のあゆみ279(4): 256-259, 2021

石原　理
遺伝子組換えヒト絨毛性ゴナドトロピンの臨床
産婦人科の実際70(11): 1175-1178, 2021

亀井良政
【産婦人科患者説明ガイド-納得・満足を引き出すために】周産期　(Q1)会陰切開は必ずやらないといけないのですか?
臨床婦人科産科75(4): 113, 2021

亀井良政
【産婦人科患者説明ガイド-納得・満足を引き出すために】周産期　(Q2)どんなときに鉗子分娩・吸引分娩をするのですか?
臨床婦人科産科75(4): 114, 2021

亀井良政
【理論と実践-新生児蘇生NCPR2020を読み解く-】清明羊水の吸引　Suctioning of clear fluid（NLS 596:ScopRev）
周産期医学51(7): 991-993, 2021

亀井良政
【産科手術を極める(II)-分娩時・産褥期の処置・手術】前方後頭位に対する鉗子遂娩術
臨床婦人科産科75(10): 956-963, 2021

亀井良政
【産科手術を極める(II)-分娩時・産褥期の処置・手術】回旋異常に対する鉗子遂娩術　前方前頭位・低在横定位に対して
臨床婦人科産科75(10): 964-970, 2021

梶原　健
【産婦人科患者説明ガイド-納得・満足を引き出すために】不妊・不育　(Q5)はっきりした原因がないのにどうして妊娠できないのですか?
臨床婦人科産科75(4): 198-200, 2021

添田純平、長谷川幸清、榊原由紀子、加瀬陽一、原　隆人
PARP阻害剤ニラパリブ　その薬剤特性と卵巣癌を中心とした開発状況
新薬と臨牀70(3): 283-299, 2021

難波　聡
産婦人科患者説明ガイド-納得・満足を引き出すために】周産期 妊娠初期 異所性妊娠に対して薬物療法を行うにあたっての患者説明
臨床婦人科産科 75(4): 17-20, 2021

田丸俊輔
【産科手術を極める(II)-分娩時・産褥期の処置・手術】子宮内反症に対する修復術
臨床婦人科産科75(10): 989-994, 2021

左　勝則、石原　理
卵巣刺激法別採卵周期あたり累積生産率の検討
産婦人科の実際 70(13): 1587-1596, 2021

藪野　彰、長谷川幸清
婦人科癌2021　プラチナ製剤感受性再発卵巣癌に対する手術療法の意義　最近の国際第III相試験の結果から
癌と化学療法48(2): 191-194, 2021

藪野　彰、長谷川幸清
【泌尿器生殖がん、婦人科がん】婦人科がん　卵巣がん、子宮がんに対する免疫チェックポイント阻害薬のエビデンス
腫瘍内科28(4): 374-380, 2021

藪野　彰、長谷川幸清
【変わる婦人科がん薬物治療-免疫チェックポイント阻害薬・PARP阻害薬を中心に-】分子標的治療薬の位置づけ　婦人科がんにおける免疫チェックポイント阻害薬
産科と婦人科88(11): 1295-1301, 2021

三輪真唯子、長谷川幸清
【希少がん-がん診療の新たな課題-】希少がん疾患各論　婦人科の腫瘍　絨毛性疾患
日本臨床79(増刊1): 398-402, 2021

小笠原仁子、長谷川幸清
【Rare tumorの最新知識】子宮体部腫瘍　明細胞癌
産婦人科の実際70(8): 841-848, 2021

佐藤　翔、藪野　彰、長谷川幸清
II 婦人科腫瘍の薬物療法のために知っておくべき遺伝子検査　3 DNAミスマッチ修復機能低下（dMMR）のための検査
産婦人科の実際70(12): 1324-1332, 2021

鷹野夏子、亀井良政
【産科手術を極める(I)-妊娠中の処置・手術】異所性妊娠に対する手術　子宮頸管妊娠・帝王切開瘢痕部妊娠への対応
臨床婦人科産科75(9): 843-849, 2021

霞澤　匠、高村将司
【産婦人科患者説明ガイド-納得・満足を引き出すために】周産期　妊娠初期　異所性妊娠手術を行うにあたっての患者説明
臨床婦人科産科75(4): 12-16, 2021